mRNA 脂质纳米粒载药系统的构建及体外评价.

Objective To construct lipid nanoparticles DLin-LNP for mRNA delivery. Methods DLin-LNP was prepared by thin film hydration method, and DLin-LNP/mRNA was further constructed by using EGFP-mRNA as model drug. The particle size, zeta potential, and appearance morphology were measured. Furthermore, the intracellular distribution and transfection of DLin-LNP/mRNA in RM-1 cells was investigated by laser scanning confocal microscope. Results DLin-LNP was successfully prepared. The average particle size was about (151.1±2.1) nm, the no-load potential was (23.7±0.5) mV. The cytotoxicity of DLinLNP was far lower than that of the commercially available liposomal Lipo8000. The results of transfection experiment indicated that DLin-LNP has high transfection efficiency for mRNA delivery with low cytotoxicity and good stability. Conclusion DLin-LNP could become a potential mRNA vector for gene therapy. [ABSTRACT FROM AUTHOR]

目的　构建脂质纳米粒 DLin-LNP, 以 EGFP-mRNA 为模型药, 考察 DLin-LNP 对于 mRNA 的体外递送能 力。方法　采用薄膜水化法制备 DLin-LNP, 并进一步制备 DLin@mRNA, 对纳米粒进行表征, 使用激光扫描共聚焦显微镜 观察脂质纳米粒胞内的分布情况, 以 RM-1 细胞为模型考察胞内转染情况。结果　成功制备了脂质纳米粒 DLin-LNP, 其粒 径为（151.1±2.1） nm, 空载电位为（23.7±0.5） mV。DLin-LNP 在 RM-1 细胞中转染 mRNA 效率较高, 其毒性远低于市售脂质 体 Lipo8000, 且 DLin-LNP 脂质纳米粒稳定性好。结论　DLin-LNP 具有高转染效率和安全性, 且稳定性好, 可作为 mRNA 递送载体, 为后续脂质纳米粒肿瘤治疗中的应用提供依据。 [ABSTRACT FROM AUTHOR]